Zacks Research Issues Optimistic Forecast for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Research analysts at Zacks Research boosted their Q1 2025 EPS estimates for shares of Halozyme Therapeutics in a research note issued on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of $0.98 for the quarter, up from their prior estimate of $0.97. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.33 EPS, FY2025 earnings at $4.50 EPS, Q3 2026 earnings at $1.38 EPS and Q4 2026 earnings at $1.63 EPS.

A number of other research analysts have also issued reports on HALO. HC Wainwright restated a “buy” rating and set a $68.00 price objective on shares of Halozyme Therapeutics in a research report on Monday, December 30th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. JMP Securities upped their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $58.00 to $62.00 in a report on Monday, October 7th. Finally, Piper Sandler increased their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $53.76 on Thursday. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The business has a 50 day moving average of $50.10 and a two-hundred day moving average of $54.00. The company has a market cap of $6.84 billion, a P/E ratio of 17.80, a PEG ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at $49,000. GAMMA Investing LLC lifted its stake in Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 350 shares in the last quarter. Toth Financial Advisory Corp acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth about $57,000. FSC Wealth Advisors LLC acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth about $65,000. Finally, Park Place Capital Corp grew its stake in Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 1,209 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $9,254,244.56. This represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.70% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.